Modi, Shanu

Publications

Sort by

Co-Author Network

selected publications

Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer cell. 2019 Academic Article GET IT
Times cited: 45
Chaperome heterogeneity and its implications for cancer study and treatment. The Journal of biological chemistry. 2018 Information Resource GET IT
Times cited: 35
Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer. JAMA dermatology. 2018 Academic Article GET IT
Times cited: 68
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. Clinical breast cancer. 2018 Academic Article GET IT
Times cited: 39
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. The oncologist. 2017 Academic Article GET IT
Times cited: 27
The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016 Academic Article GET IT
Times cited: 201
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. Breast cancer research : BCR. 2016 Academic Article GET IT
Times cited: 42
Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. Discovery medicine. 2016 Academic Article GET IT
Times cited: 78
Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. Clinical breast cancer. 2015 Academic Article GET IT
Times cited: 10
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical breast cancer. 2015 Academic Article GET IT
Times cited: 1
Ganetespib: research and clinical development. OncoTargets and therapy. 2015 Information Resource GET IT
Times cited: 82
The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation. Annals of surgical oncology. 2015 Academic Article GET IT
Times cited: 51
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 71
Ex vivo treatment response of primary tumors and/or associated metastases for preclinical and clinical development of therapeutics. Journal of visualized experiments : JoVE. 2014 Academic Article GET IT
Times cited: 12
Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert opinion on investigational drugs. 2014 Information Resource GET IT
Times cited: 139
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clinical breast cancer. 2013 Academic Article GET IT
Times cited: 69
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. Nuclear medicine communications. 2013 Academic Article GET IT
Times cited: 66
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Breast cancer research and treatment. 2013 Academic Article GET IT
Times cited: 54
Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer prevention research (Philadelphia, Pa.). 2013 Academic Article GET IT
Times cited: 61
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 179
A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 46
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer. 2012 Academic Article GET IT
Times cited: 68
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 253
HSP90 inhibitors for cancer therapy and overcoming drug resistance. Advances in pharmacology (San Diego, Calif.). 2012 Article GET IT
Times cited: 59
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochimica et biophysica acta. 2011 Information Resource GET IT
Times cited: 410
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. Journal of clinical pharmacology. 2011 Academic Article GET IT
Times cited: 57
Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Editorial Article GET IT
Times cited: 4
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 315
Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert opinion on drug discovery. 2011 Academic Article GET IT
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 51
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 25
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 441
Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results. Clinical breast cancer. 2010 Academic Article GET IT
Times cited: 5
HER2 breast cancer therapies: a review. Biologics : targets & therapy. 2009 Academic Article GET IT
The heat shock protein 90 chaperone complex: an evolving therapeutic target. Current cancer drug targets. 2008 Information Resource GET IT
Times cited: 47
Trastuzumab-refractory HER2-positive metastatic breast cancer - Use of tanespimycin, a novel Hsp90 inhibitor. American Journal of Hematology/ Oncology. 2008 Article
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 293
A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clinical breast cancer. 2006 Academic Article GET IT
Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005 Academic Article GET IT
Times cited: 152
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clinical breast cancer. 2005 Academic Article GET IT
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast cancer research and treatment. 2005 Academic Article GET IT
Times cited: 76
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer investigation. 2005 Academic Article GET IT
Times cited: 38
Single-agent gemcitabine in the treatment of advanced breast cancer. Clinical Breast Cancer. 2004 Article
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 25
An update on epidermal growth factor receptor inhibitors. Current oncology reports. 2002 Information Resource GET IT
Times cited: 26
Biomonitoring of urinary tamoxifen and its metabolites from breast cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrometry. Electrophoresis. 2001 Academic Article GET IT
Times cited: 34
Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clinical lung cancer. 2001 Academic Article GET IT
The cancer patient with chronic pain due to herpes zoster. Current review of pain. 2000 Information Resource GET IT
Times cited: 9

more ...

less ...

Background

education and training

B.A., University of Alberta (Canada) 91
M.D., University of Alberta Faculty of Medicine (Canada) 1995

Contact

full name

Shanu Modi

VIVO Weill Cornell Medical College

Shanu Modi Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name